Measuring the precise dynamics of specific neurotransmitters and neuromodulators in the brain is essential for understanding how information is transmitted and processed. Thanks to the development and optimization of various genetically encoded sensors, we are approaching the stage in which a few key neurotransmitters/neuromodulators can be imaged with high cell specificity and good signal-to-noise ratio. Here, we summarize recent progress regarding these sensors, focusing on their design principles, properties, potential applications, and current limitations. We also highlight the G protein-coupled receptor (GPCR) scaffold as a promising platform that may enable the scalable development of the next generation of sensors, enabling the rapid, sensitive, and specific detection of a large repertoire of neurotransmitters/neuromodulators in vivo at cellular or even subcellular resolution.
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Introduction
In the mammalian central nervous system, several billions of interconnected neurons control a wide range of key physiological processes, from basic sensation and motor control to higher brain cognitive functions such as memory, decision-making, and self-awareness. The communication between neurons is mediated predominantly via a specialized structure called the synapse, in which neurotransmitters are enriched in synaptic vesicles at the presynaptic terminal; these transmitters are released into the synaptic cleft when action potentials invade the terminal, thereby activating or inhibiting the postsynaptic neuron.
Classic neurotransmitters, such as glutamate and GABA, by generally activating ionotropic receptors, mediate the extremely fast, spatially confined, point-to-point synaptic transmission. Neuromodulators such as dopamine and neuropeptides, typically by acting on metabotropic G protein-coupled receptors (GPCRs) to initiate downstream signal cascades, are thought to mediate neurotransmission, at least in part by a relatively slow, long-range, diffuse form, called volume transmission. The exact mode of action for neurotransmitters/neuromodulators is complex, because they are capable of activating both ionotropic receptors and GPCRs, with multiple isoforms that have distinct affinities and/or diverse intracellular effectors. Not surprisingly, dysregulation of neurotransmitter and/or neuromodulator release has been linked to many neurological disorders, including depression, schizophrenia, dementia, and neurodegenerative diseases [1] [2] [3] .
Given these essential functions that neurotransmitters and neuromodulators play in the brain, the ability to monitor their dynamics is critical for understanding their regulation and activity at the molecular, cellular, and circuit levels. However, tracking specific neurotransmitters with high precision is extremely challenging due to the complex nature of the central nervous system with respect to its anatomical and chemical features. Each individual neuron is essentially a functionally isolated unit with distinct intrinsic physiological properties, as well as a unique molecular signature; thus, neurons respond heterogeneously to stimuli. Moreover, billions of neurons in the brain are connected both anatomically and functionally by excitatory and inhibitory processes mediated by fast synaptic transmission and/or slow volume transmission. As a consequence of this connectivity, neurotransmitter levels are regulated by individual neurons even in subcellular compartments, as well as by complicated circuits across different brain regions. This configuration demands the highly specific detection of neurotransmitters and neuromodulators, with high temporal and spatial resolution that can match the dynamics of the central nervous system. On the other hand, each neurotransmitter/neuromodulator has a unique set of chemical properties, ranging from amino acids to monoamines, purines, and peptides. This creates an obvious biological dilemma: any general detection method would need to cover the entire spectrum of chemically diverse transmitters, while still retaining the specific ability to discriminate between different transmitters.
To overcome this challenge, in recent decades several pioneering research tools have been developed and refined for measuring the dynamics of neurotransmitters and neuromodulators. These tools are designed to sense various features of neurotransmission, and they vary with respect to their detection sensitivity and specificity, temporal and spatial resolution, cell specificity and invasiveness. Here, we provide an overview of these sensors' design principles, properties, and current limitations, focusing on genetically encoded fluorescent sensors, which are ideally suited to track the precise dynamics of neurotransmitters and neuromodulators.
Detecting neurotransmitters/ neuromodulators using optical imaging
Compared with traditional methods such as microdialysis (Figure 1a ), current recording, and electrochemical detection (Figure 1b ), optical imaging is widely accepted as a non-invasive, high-throughput method for tracking specific molecules, building upon the foundation of fluorescent probes. Unlike tools that directly measure the concentration of neurotransmitters/neuromodulators, synthetic FM dyes [4] , quantum dots [5] , fluorescent false neurotransmitters (FFNs) [6] , and pH-sensitive fluorescent proteins [7] [8] [9] have all been used to image the exocytosis of synaptic vesicles, which indirectly reflects the release of neurotransmitters. Despite their advantages and widespread usage, however, these methods either lack molecular specificity or have relatively low temporal resolution due to vesicle recycling.
To directly measure the dynamics of a specific type of neurotransmitter using optical imaging, a protein-based optical reporter must include two key features. First, it must be able to recognize or bind directly and specifically to its cognate neurotransmitter and change its conformation. Second, the reporter must produce an optical signal that is sensitive to the change in the protein's conformation. To achieve the first goal, various scaffolds have been generated, including mammalian neurotransmitter receptors (either ionotropic or metabotropic), neurotransmitterbinding proteins isolated from bacterial periplasm, and enzymes that utilize the neurotransmitter as the substrate (e.g. acetylcholinesterase, which catalyzes the breakdown of acetylcholine). The corresponding optical output (i.e. the signal) can be generated using various approaches that include a change in first, the fluorescence of a synthetic dye, or a single fluorescent protein, second, a FRET/ BRET (fluorescence/bioluminescence resonance energy transfer) signal produced by a pair of donor and acceptor proteins, or third, expression of an optical reporter gene (i. e. a luciferase). Based on their genetical encodability, we can classify each of these methods as either a hybrid sensor composed of a chemical synthetic dye with a protein binding partner, or a fully genetically encoded sensor.
Hybrid sensors for imaging neurotransmitters and neuromodulators
The hybrid sensor E(glutamate) optical sensor (EOS) was developed to report glutamate, the predominant excitatory neurotransmitter in the mammalian brain; this sensor contains a chemically linked fluorescent dye (Oregon Green) located near the glutamate-binding pocket of the GluR2 metabotropic glutamate receptor [10] . The dynamic range of the first-generation EOS was approximately 20%, and it could only report glutamate signals in simple cultured preparations. To overcome these practical limitations, a series of optimized EOS variants were developed with increases in both the dynamic range of the fluorescent signal and the affinity for glutamate, enabling researchers to monitor the dynamics of extrasynaptic glutamate in the brain during physiological stimuli [11] .
Another class of hybrid neurotransmitter sensors, Snifits (SNAP-tag based indicator proteins with a fluorescent intramolecular tether), was constructed by labeling the neurotransmitter-binding protein with a SNAP-taglinked fluorescent ligand and a CLIP-tag-linked fluorophore (see Table 1 ). The fluorescent ligand and the fluorophore form a FRET pair, and the energy transfer efficiency shifts when the endogenous ligand competes for binding (Figure 1c) . Snifits have been used in cultured cells to image the dynamics of several transmitters, including GABA [12] , glutamate [13] , and acetylcholine (ACh) [14 ] , yielding significant changes in the FRET ratio. However, Snifits have not been tested in vivo; therefore, whether they have enough sensitivity to detect transmitter dynamics in the intact brain is currently unknown. Another group of hybrid sensors using the FlAsH-CFP FRET pair inserted in GPCRs will be elaborated below in GPCR-based sensors.
Overall, hybrid sensors provide relatively sensitive and selective detection of specific neurotransmitters. However, because they require a synthetic dye to label the genetically encoded tag, their usage in behaving animals is limited due to low tissue penetrance and relatively high background signals.
Genetically encoded sensors for imaging neurotransmitters and neuromodulators
To avoid the need of exogenously applying a synthetic fluorophore for labeling, genetically encoded optical reporters provide cell-specific expression and transmitter detection, which is essential for monitoring specific neurotransmitters and neuromodulators in the context of the highly complex central nervous system. Based on the type of neurotransmitter-binding protein, these sensors are generally classified as either bacterial periplasmicbinding protein (PBP)-based sensors or GPCR-based sensors.
PBP-based sensors
Bacterial periplasmic-binding proteins (PBPs) comprise a large, diverse superfamily of proteins that bind various chemicals, including neurotransmitters; thus, these proteins provide a suitable scaffold for biosensor engineering. The Escherichia coli-derived glutamate-binding PBP GltI (also known as ybeJ) was used to generate a series of glutamate-sensing fluorescent indicators (FLIPE and GluSnFRs) by fusing the CFP-YFP FRET pair to the protein [15, 16] . Further engineering refinements, including changing the insertion site of the FRET pairs and random mutagenesis, have increased the signal's dynamic range to nearly 50% [17, 18] . Although these optimized GltI/FRET-based glutamate sensors have high affinity and rapid kinetics (around the 10-ms level), their application in vivo has been hampered by their relatively low signal-to-noise ratio.
To increase the signal of PBP-based sensors, a new intensity-based fluorescent glutamate sensor (iGluSnFR) was engineered by combining circular permutated EGFP (cpEGFP) with the PBP GltI [19 ] (Figure 1d ). This next-generation sensor produces a bright, rapid, and specific fluorescence increase upon glutamate binding, with a large dynamic range (peak DF/F 0 values of 4.5 and 1.0 in cultured HEK-293 cells and neurons, respectively).
The ability of iGluSnFR to detect glutamate release in vivo was demonstrated using several model organisms, including Caenorhabditis elegans, zebrafish, and mice [19 ] . Recent developed red version R-iGluSnFR1 further expanded the color palette of glutamate sensors [20] . Overall, the iGluSnFR sensor provides high sensitivity and specificity for detecting glutamate in a cell-specific manner, thereby providing important information regarding the in vivo dynamics of glutamatergic transmission.
GPCR-based sensors
G protein-coupled receptors (GPCRs) constitute the majority of receptors for neurotransmitters and neuromodulators, with a conserved structural topology and high specificity for endogenous neurotransmitters. In 2003, Vilardaga and colleagues generated a series of ratiometric FRET-based sensors called GPCR-cam by inserting a pair of FRET proteins in the receptor's third intracellular loop and C-terminal domain (Figure 1e ). Upon binding the ligand, the resulting conformational change of the receptor shifts the distance and orientation between the FRET pair, thereby changing FRET efficiency. Using this strategy, PTHR-cam and a 2A AR-cam were generated based on the parathyroid hormone receptor and a 2A -adrenergic receptor, respectively [21] . However, reminiscent of the FRET sensors created with PBPs, the change in GPCR-cam FRET efficiency is relatively small (<10%) [21] , and trafficking of the GPCR-cam protein is affected by the presence of two relatively large fluorescent proteins. Therefore, to improve the expression and delivery of these sensors to the plasma membrane, and to increase the resulting FRET signals, a different FRET pair -CFP and the fluorophore FIAsH -was used. Using this FRET pair, sensors for detecting epinephrine and acetylcholine were engineered with the b 2 -adrenergic receptor [22] and the muscarinic acetylcholine receptor [23 ,24] , respectively, as the scaffold. These FRET sensors have high binding affinity for their respective ligands and millisecond temporal resolution; however, the relatively small change in FRET signal and the need to load the FlAsH-CFP pair with an exogenous fluorescent dye limits their feasibility in in vivo systems.
To overcome the relative small conformational change induced by neurotransmitter binding to the GPCR, the signal can be amplified by detecting the downstream signaling molecules activated by the GPCR, or by inducing the expression of a reporter gene via activating a transcription factor. Thus, a series of cell-based neurotransmitter fluorescent engineered reporters (CNiFERs) were developed in order to report the change in intracellular Ca 2+ following GPCR activation (Figure 1f ). Cultured HEK cells expressing specific GPCRs and the ratiometric fluorescent Ca 2+ sensors were then implanted into specific regions in the brain, serving as a reporter unit to transmit extracellular neurotransmitter signals into a change in fluorescence. Using this approach, CNiFERs have been used successfully to sense acetylcholine [25] , dopamine, and norepinephrine [26 ] in vivo. Despite their ability to report specific neurotransmitters with high sensitivity, the invasive nature of cell implantation required in CNiFERs hinders their broad application.
Based on the downstream signal transduction cascades activated by GPCRs, the TANGO assay was designed to capture and transmit GPCR activation into a stable intracellular signal [27] (Figure 1g ). In this system, the transcription factor tTA is fused to the C-terminal domain of the GPCR by a peptide sequence containing a TEV (tobacco etch virus) protease cleavage site, which is cleaved when TEV protease-fused b-arrestin is recruited upon GPCR activation. This cleavage event releases tTA from the receptor, allowing it to translocate to the nucleus and initiate expression of a reporter gene (e.g. luciferase or a fluorescent protein) for optical detection. By signal amplification, the TANGO assay provides single-cell resolution, nanomolar sensitivity for specific neurotransmitters. Importantly, this system also circumvents the confounding effects associated with implanting exogenous cells in CNiFERs, as the signaling molecules are genetically encoded and could be target-expressed in desirable cells by various genetic techniques. This method has been used successfully to detect in vivo dopaminergic signaling in both Drosophila and mice [28, 29 ] , and very recently a derived trans-Tango method has been used to map anterograde synaptic circuits in olfactory and gustatory systems of Drosophila [30] .
However, the high signal amplification provided by this assay comes at a cost: temporal resolution is poor (around hours or more), making this approach unsuitable for realtime neurotransmitter/neuromodulator measurements. An improved iTANGO and its simplified version iTANGO2 were recently developed [29 ] , where a clever light-controlled system was additionally implemented to gate the protease cleavage and the subsequent transcription factor activation (Figure 1h ). Similar in design principle, SPARK method developed by Ting's group was shown to yield up to 37-fold signal increase upon activation by specific neuromodulators, with $5-minute temporal resolution [31] . In comparison to the previous TANGO approach, iTANGO2 and SPARK reduce background signals and yield better temporal resolution ($ minutes) to detect neuromodulators, that is, dopamine. Judicious usage of dCas9 [32] or split dCas9 [33] based transcription amplification systems in a TANGO style design could achieve the flexibility to activate endogenous genes at will and could further increase relative signal strength over background. These improved strategies have not been validated in vivo yet, however, the sub-second or second kinetics of neurotransmitters/neuromodulators is still beyond the temporal resolution of above transcription assays and the irreversible nature of protease cleavage precludes this method to continuously monitor the dynamics of neurotransmitters/ neuromodulators in real time.
In summary, genetically encoded neurotransmitter sensors provide improved ligand selectivity, spatial sensitivity, and cell specificity especially for in vivo applications, although majority existing sensors have their own constrains in either signal-to-noise ratio or temporal resolution (Figure 1 ).
Future directions
The famous South African molecular biologist and Nobel laureate Sydney Brenner stated that 'Progress in science depends on new techniques, new discoveries, and new ideas, probably in that order.' Indeed, understanding the complex nature of the mammalian brain calls for new research tools that can measure the dynamics of key neurotransmitters and neuromodulators with high specificity, single-cell spatial resolution, and physiologically relevant temporal resolution, ideally in an in vivo setting. Genetically encoded fluorescent sensors fulfill these criteria and can provide important information regarding the functional properties and dynamics of neurotransmitters in the brain. In general, the scaffold used to engineer genetically encoded sensors need to provide high ligand specificity and can -at least in principle -be adapted for sensing all neurotransmitters and neuromodulators. With respect to PBP-based sensors, the iGluSnFR represents an important step forward in terms of providing a highly specific and sensitive in vivo sensor for glutamate; however, whether the same strategy can be scaled up and applied to measure other neurotransmitters or neuromodulators, and whether these transmitters/modulators can be reliably detected under physiological conditions, remain open questions, especially for peptide neuromodulators that do not have a corresponding cognate PBP in bacteria. On the other hand, GPCRs are evolutionarily conserved and have retained both specificity and affinity for nearly all neurotransmitters; thus, GPCRs may provide a better scaffold for developing the next generation of sensors.
Indeed, by tapping into the GPCR scaffold, our group recently developed an ACh sensor with high signal-tonoise ratio [34 ] . Taking advantage of the environmental sensitive cpEGFP to report the conformational change during GPCR activation, we incorporated cpEGFP into a human muscarinic GPCR (Figure 1i) . By optimizing the membrane trafficking as well as the conformational coupling between the GPCR and cpEGFP through iterative site-directed mutagenesis, we generated an GACh sensor (short for the G-protein-coupled receptor activationbased AChsensors) that could readily achieve 90% DF/ F 0 fluorescence increase upon ACh application in both cultured HEK293T and cortical neurons. GACh sensors also have micro-molar affinity and high specificity to ACh as well as sub-second response kinetics (see Table 1 ). GACh sensors were further validated in multiple in vivo systems including Drosophila and mice, capable of detecting the endogenous ACh dynamics in physiological relevant settings [34 ] . Importantly, the rich structural information for various GPCRs in both active and inactive states currently available reveals that diverse GPCRs share similar activation mechanisms [35] [36] [37] . Thus, the strategy to generate GACh sensors [34 ] , in principle, could be extended and applied to develop other neurotransmitter/neuromodulator sensors with high sensitivity and specificity, despite the fact that considerable challenges still remain for engineering seven-transmembrane proteins to harness their subtle ligand-induced conformational changes. As a note, attention needs to be paid to ensure the GPCR based sensors do not perturb the intrinsic physiology in the cell of interest, given a plethora of intracellular signaling pathways GPCRs involved. Looking ahead, in addition to PBPs and GPCRs, neurotransmitter transporter proteins may also serve as a viable scaffold for new sensors, particularly due to their high specificity and affinity for their respective ligands, as well as their conserved structures. Colorwise, a single-wavelength sensor cannot be used to map the entire spectrum of neurotransmission, as several neurotransmitters can interact simultaneously at a single site or at different subcellular compartments, including axons, dendrites, cilia, and axon initial segments, thereby providing the network with highly precise functional control. Therefore, using multicolor imaging of sensors with non-overlapping spectrums -or using bioluminescence, which provides better tissue penetration -will likely yield valuable information regarding the processes through which neurotransmitters are spatially and dynamically controlled in order to coordinate their complex functions within the brain. Moreover, the simultaneous application of optical actuators such as channel rhodopsin-based optogenetic tools may help to bridge the cause-and-effect relationship between specific neurotransmitters and behavioral output. Finally, probing the dynamics of specific neurotransmitters in various disease models may provide researchers with important information regarding the underlying pathogenic mechanisms, thereby yielding new targets for rational drug design and new therapeutic approaches.
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